Le Lézard
Classified in: Health
Subjects: PDT, SCZ

BioPhotas, Inc. Launches the Newest Model of the Celluma Series


ANAHEIM, Calif., Jan. 3, 2018 /PRNewswire/ -- BioPhotas, Inc. announces the commercial introduction of the Celluma HOME, a fourth model in the Celluma Series of light therapy devices. Offered at an introductory price of $599.00, the Celluma HOME specifically addresses the challenges of Baby Boomers who struggle with wrinkles, aches and pain. FDA-cleared for over-the-counter purchase, the Celluma HOME treats eight separate aging challenges faced by the Baby Boomer, including full face wrinkles, arthritis, muscle and joint pain, muscle spasms and poor blood circulation.

Commenting on the launch of the Celluma HOME, Patrick Johnson, President & Chief Executive Officer for BioPhotas said, "From the very start, our goal at BioPhotas was to bring an FDA-cleared medical device directly to the consumer at home with the efficacy of large professional panels, but with the affordability of small hand-held devices. We believe we have achieved this with the Celluma HOME. Designed to treat a wide range of skin, muscle and joint conditions, anywhere on the body, the Celluma HOME gives the consumer the benefit of multiple hand-held devices in a single light panel with a significantly larger in treatment area."  

The Celluma HOME delivers blue, red and near-infrared light energy to safely address a wide variety of musculoskeletal and dermatological conditions. Each wavelength is absorbed by different molecules which act as a signaling mechanism for different cellular processes. With a treatment area that measures 14" by 6", the Celluma HOME is several times larger than typical hand-held light therapy devices. The Celluma's patented shape-taking light panel facilitates effective energy absorption by tissue by molding closely to any apart of the body, producing more efficient outcomes. 

The Celluma Series of light therapy devices is protected by both United States and Foreign utility patents and is CE-marked as a Dermal Wound Healing device. Further commenting on the launch of the Celluma HOME, Mr. Johnson noted, "[T]he Celluma HOME is a two-mode device designed specifically for the Baby Boomer who is interested in looking better and feeling better, and who wants to address those desires in the convenience of their own home." 

About BioPhotas, Inc.
In providing unique devices founded on NASA-developed technology and backed by clinical studies, BioPhotas is bringing to market safe, effective and affordable devices that unlock the clinical power of biophotonics. BioPhotas develops and markets devices for healthcare providers and consumers that conveniently treat a variety of skin, muscle and joint conditions. For more information about the Celluma please visit www.biophotas.com.

CONTACT:                                                                  
Patrick Johnson ? CEO
BioPhotas, Inc.
[email protected] 
7149780080

SOURCE BioPhotas, Inc.


These press releases may also interest you

at 19:40
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

at 19:05
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

at 19:00
David J. Dykeman, co-chair of the Life Sciences & Medical...

at 18:30
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...

at 17:21
Chemistree Technology Inc. (US OTC: CHMJF) (the "Company" or "Chemistree"), is pleased to announce that the adjourned extraordinary meeting of the holders of the 10% senior unsecured convertible debentures of the Company (the "Debentures") was...

at 17:15
Summary Product: Counterfeit Viagra, 100 mg sildenafil tabletsIssue: Health products - Product safety, Unauthorized productWhat to do: Immediately stop using and safely dispose of this product. Consult your health care provider if you have taken this...



News published on and distributed by: